LONDON, UK / ACCESS Newswire / May 23, 2026 / MYTRT, a UK-based digital healthcare platform, has announced the launch of a service for people seeking information, testing and clinical assessment ...

Study conducted with Severance Hospital shows whole-genome sequencing-based HRD phenotyping was associated with longer progression-free survival in patients receiving PARP inhibitor maintenance ...

BFA Law is investigating whether Intuit committed securities fraud relating to its representations about TurboTax’s price positioning among DIY tax filers ahead of and during the 2026 tax season.NEW ...

VANCOUVER, BC / ACCESS Newswire / May 22, 2026 / GLG Life Tech Corporation (NEX:GLG.H) ("GLG" or the "Company"), a global leader in the agricultural and commercial development of high-quality ...

Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Phreesia Inc. (“Phreesia” or the “Company”) (NYSE ...

Future facility will serve to broaden access to affordable continuing education and hands-on training for dentists IRVINE, CA / ACCESS Newswire / May 22, 2026 / Glidewell, America's leading dental ...

Proposed dual listing expected to broaden access to US investors as buloxibutid advances toward its Phase 2b readout in IPF, with no concurrent financing or share offering planned STOCKHOLM, SWEDEN ...

Late-breaking Phase 3 SUCCESSOR-2 study results highlight potential of mezigdomide, a novel CELMoD from the Company’s targeted protein degradation platform, in relapsed or refractory multiple ...

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with AgiosAvanzanite is ...

VANCOUVER, BC / ACCESS Newswire / May 22, 2026 / LIR Life Sciences Corp. (CSE:SKNY)(OTCPK:BBCMF)(Frankfurt:N790, WKN:A41QA9) ("LIR" or the "Company")is pleased to announce that Neuland Laboratories ...

SAGA Diagnostics, a pioneer in ultrasensitive molecular residual disease (MRD) detection and precision oncology, today announced that the company and key collaborators will present data from three ...

Two-year and post-hoc SURPASS-ET analyses highlight the impact of treatment timing, with durable responses and improved progression-free survival supporting consideration of earlier ropeginterferon ...